Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Connections between psoriasis and Crohn's disease.

David James Najarian1, Alice B Gottlieb

  • 1University of Virginia School of Medicine, USA.

Journal of the American Academy of Dermatology
|June 6, 2003
PubMed
Summary

Psoriasis and Crohn's disease share genetic and pathological links, particularly involving tumor necrosis factor-alpha. Targeting this inflammatory mediator with infliximab shows promise for treating both conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.

The Journal of clinical and aesthetic dermatology·2026
Same author

Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting.

The Journal of rheumatology·2026
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026
Same author

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA dermatology·2026
Same author

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Area of Science:

  • Dermatology and Gastroenterology
  • Immunology and Genetics

Background:

  • Psoriasis and Crohn's disease (CD) exhibit a higher than chance co-occurrence.
  • Shared epidemiological, genetic, and pathological factors link these distinct conditions.

Purpose of the Study:

  • To review the connections between psoriasis and CD.
  • To discuss therapeutic strategies targeting common inflammatory mediators.

Main Methods:

  • Review of epidemiological, genetic, and pathological data.
  • Analysis of the role of tumor necrosis factor-alpha (TNF-α).
  • Evaluation of infliximab efficacy in clinical trials.

Main Results:

  • Elevated TNF-α levels are observed in lesions of both CD and psoriasis.
  • Infliximab, a TNF-α inhibitor, demonstrated efficacy in treating CD and subsequently psoriasis.
  • A case study and randomized trial confirmed infliximab's benefit for psoriasis in a CD patient.

Conclusions:

  • Understanding the links between psoriasis and CD can inform novel therapeutic approaches.
  • Targeting shared inflammatory pathways, like TNF-α, offers potential benefits for patients with either or both conditions.

Related Experiment Videos